Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer

2013 ◽  
Vol 41 (1) ◽  
pp. 89-101 ◽  
Author(s):  
Ralf Lesche ◽  
Georg Kettschau ◽  
Alexey V. Gromov ◽  
Niels Böhnke ◽  
Sandra Borkowski ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Prostate Specific Membrane Antigen ◽  
Preclinical Evaluation ◽  
Specific Membrane

scholarly journals PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen

2013 ◽  
Vol 13 (8) ◽  
pp. 951-962 ◽  
Author(s):  
Ronnie C. Mease ◽  
Catherine A. Foss ◽  
Martin G. Pomper
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

scholarly journals Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging

2021 ◽  
Author(s):  
Katharina Kessel ◽  
Robert Seifert ◽  
Matthias Weckesser ◽  
Martin Boegemann ◽  
Sebastian Huss ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Pet Imaging ◽  
Fibroblast Activation Protein ◽  
Prostate Specific Membrane Antigen ◽  
Psma Pet ◽  
Node Metastases ◽  
Small Patient ◽  
Specific Membrane ◽  
Psma Expression

Abstract Introduction Fibroblast activation protein (FAP) has been recently presented as new imaging target for malignant diseases and offers high contrast to surrounding normal tissue. FAP tracer uptake has been reported in various tumor entities. The aim of this study was to compare FAP and Prostate-specific membrane antigen (PSMA) expression in primary prostate cancer employing histological analyses and PET imaging in two small patient collectives. Methods Two independent small patient collectives were included in this study. For cohort A, data of 5 prostate cancer patients and 3 patients with benign prostate hyperplasia were included. Patients with prostate cancer were initially referred for PSMA PET staging. Radical prostatectomy was performed in all patients and prostate specimen of patients and biopsies of healthy controls were available for further evaluation. Histological workup included HE and immunohistochemistry using PSMA Ab, FAP Ab. Cohort B consists of 6 Patients with diagnosed mCRPC and available PSMA as well as FAP PET. Results Patients with proven prostate cancer infiltration exhibited strong positivity for PSMA in both primary tumors and lymph node metastases while stainings for FAP were found positive in some cases, but not all (2/5). Controls with BPH presented moderate PSMA staining and in one case also with a positive FAP staining (1/3). PET imaging with FAP seemed to result in more precise results in case of low PSMA expression than PSMA-PET. Conclusions While PSMA staining intensity is a valid indicator of prostate cancer in both primary tumor and lymph node metastases, the expression of FAP seems to be heterogeneous but not necessarily linked to cancer-associated fibroblasts. It is also present in inflammation-associated myofibroblasts. Therefore, its ultimate role in prostate cancer diagnosis remains a subject of discussion.

scholarly journals Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

2015 ◽  
Vol 17 (4) ◽  
pp. 565-574 ◽  
Author(s):  
Zsolt Szabo ◽  
Esther Mena ◽  
Steven P. Rowe ◽  
Donika Plyku ◽  
Rosa Nidal ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Initial Evaluation ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

scholarly journals Preclinical Evaluation of 18 F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging

2016 ◽  
Vol 58 (3) ◽  
pp. 425-431 ◽  
Author(s):  
Jens Cardinale ◽  
Martin Schäfer ◽  
Martina Benešová ◽  
Ulrike Bauder-Wüst ◽  
Karin Leotta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Imaging ◽  
Prostate Specific Membrane Antigen ◽  
Preclinical Evaluation ◽  
Specific Membrane

scholarly journals Imaging standardization systems for hybrid PET imaging of prostate cancer with radiolabeled prostate-specific membrane antigen ligands: comparative review of PROMISE and PSMA-RADS version 1.0

2019 ◽  
pp. 90-99
Author(s):  
A. V. Leontyev ◽  
N. A. Rubtsova ◽  
A. I. Khalimon ◽  
M. T. Kuliev ◽  
I. V. Pylova ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Prostate Specific Membrane Antigen ◽  
Advantages And Disadvantages ◽  
Comparative Review ◽  
Two Systems ◽  
Specific Membrane

This article provides a comparative review of two systems for standardized evaluation of the results of hybrid PET imaging with radiolabeled PSMA ligands – PROMISE and PSMA-RADS version 1.0. The principles of classification, nomenclature and evaluation algorithms, as well as recommendations for structuring research and conclusion protocols, highlighting the advantages and disadvantages of the proposed systems, are considered in detail.

PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16038-e16038 ◽  
Author(s):  
Tobias Maurer ◽  
Juergen Gschwend ◽  
Hans-Juergen Wester ◽  
Michael Souvatzoglou ◽  
Ambros Beer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Prostate Specific Membrane Antigen ◽  
Primary Prostate Cancer ◽  
Specific Membrane

Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Justin Ferdinandus ◽  
Wolfgang Peter Fendler ◽  
Boris Hadaschik ◽  
Ken Herrmann
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Cancer Recurrence ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Recurrence ◽  
Specific Membrane
Sign in / Sign up

Export Citation Format

Share Document